How much is more life worth?

Hastings Center Report

Volumn 36, Issue 3, 2006, Pages 17-19

  Brock, Dan W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY;

COST BENEFIT ANALYSIS; DRUG COST; DRUG INDUSTRY; ECONOMICS; ETHICS; HUMAN; PATENT; QUALITY ADJUSTED LIFE YEAR; SHORT SURVEY; SOCIOECONOMICS; UNITED KINGDOM; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INDUSTRY; GREAT BRITAIN; HUMANS; PATENTS; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; VALUE OF LIFE;

EID: 33745922081     PISSN: 00930334     EISSN: None     Source Type: Journal    
DOI: 10.1353/hcr.2006.0036     Document Type: Short Survey

References (7)

1. A. Berenson, "A Cancer Drug Shows Promise, at a Price That Many Can't Pay," New York Times, February 15, 2006.
2. Ibid.
3. S.R. Tunis, "Why Medicare Has Not Established Criteria for Coverage Decisions," New England Journal of Medicine 350 (2004): 2196-98.
4. M.R. Gillick, "Medicare Coverage for Technological Innovations - Time for New Criteria?" New England Journal of Medicine 350 (2004): 2199-203.
5. M.D. Rawlins and A.J. Culyer, "National Institute for Clinical Excellence and Its Value Judgments," British Medical Journal 329 (2004): 224-27.
6. W.K. Viscusi, "The Value of Risks to Life and Health," Journal of Economic Literature 31 (December 1993): 1912-46;
7. W.C. Winkelmayer et al., "Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment," Medical Decision Making 22 (September-October 2002): 417-30.